Aclarion Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
ACON$1.66+6.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Changes in Stockholders' Equity
Condensed Statements of Changes in Stockholders' Equity (Deficit)
(Unaudited)
| Series A · Series A-1, A-2, A-3, A-4 · Series B, B-1 · Series B-2, B-3 | ||||||||
|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Preferred Stock · Preferred Stock · Preferred Stock | ||||||||
| Shares | Value | Shares | Value | Shares | Value | Shares | Value* | |
| Balance, December 31, 2022 | – | $– | – | $– | – | $– | – | $– |
| Share-based compensation | – | – | – | – | – | – | – | – |
| Proceeds from sale of Series A preferred stock | 1 | 1,000 | – | – | – | – | – | – |
| Redemption of Series A Preferred stock | (1) | (1,000) | – | – | – | – | – | – |
| Net income (loss) | – | – | – | – | – | – | – | – |
| Balance, March 31, 2023 | – | $– | – | $– | – | $– | – | $– |
| Share-based compensation | – | – | – | – | – | – | – | – |
| Commitment shares - note financing | – | – | – | – | – | – | – | – |
| Issuance of warrants - note financing | – | – | – | – | – | – | – | – |
| Net income (loss) | – | – | – | – | – | – | – | – |
| Balance, June 30, 2023 | – | $– | – | $– | – | $– | – | $– |
| Balance, December 31, 2023 | – | $– | – | $– | – | $– | – | $– |
| Share-based compensation | – | – | – | – | – | – | – | – |
| Issuance of common shares related to restricted stock units | – | – | – | – | – | – | – | – |
| Issuance of common shares - equity line of credit | – | – | – | – | – | – | – | – |
| Issuance of commitment shares - note financing | – | – | – | – | – | – | – | – |
| Cashless exercise of pre-funded warrants | – | – | – | – | – | – | – | – |
| Issuance of common stock and warrants related to public offering, net issuance costs | – | – | – | – | – | – | – | – |
| Public offering and line of credit issuance costs | – | – | – | – | – | – | – | – |
| Issuance of common shares - debt for equity exchange | – | – | – | – | – | – | – | – |
| Round up conversion related to reverse stock split | – | – | – | – | – | – | – | – |
| Net income (loss) | – | – | – | – | – | – | – | – |
| Balance, March 31, 2024 | – | $– | – | $– | – | $– | – | $– |
| Share-based compensation | – | – | – | – | – | – | – | – |
| Issuance of common shares related to restricted stock units | – | – | – | – | – | – | – | – |
| Issuance of common shares - equity line of credit | – | – | – | – | – | – | – | – |
| Net income (loss) | – | – | – | – | – | – | – | – |
| Balance, June 30, 2024 | – | $– | – | $– | – | $– | – | $– |
(continued)
Condensed Statements of Changes in Stockholders' Equity (Deficit)
(Unaudited)
(continued)
| Additional | |||||
|---|---|---|---|---|---|
| Common Stock · Paid-In · Accumulated | |||||
| Shares | Value | Capital | Deficit | Total | |
| Balance, December 31, 2022 | 491,345 | $5 | $41,596,106 | $(39,370,153) | $2,225,958 |
| Share-based compensation | – | – | 82,531 | – | 82,531 |
| Proceeds from sale of Series A preferred stock | – | – | – | – | 1,000 |
| Redemption of Series A Preferred stock | – | – | – | – | (1,000) |
| Net income (loss) | – | – | – | (1,183,460) | (1,183,460) |
| Balance, March 31, 2023 | 491,345 | $5 | $41,678,637 | $(40,553,613) | 1,125,029 |
| Share-based compensation | – | – | 136,631 | – | 136,631 |
| Commitment shares - note financing | 21,210 | – | 175,619 | – | 175,619 |
| Issuance of warrants - note financing | – | – | 37,500 | – | 37,500 |
| Net income (loss) | – | – | – | (1,464,557) | (1,464,557) |
| Balance, June 30, 2023 | 512,555 | $5 | $42,028,387 | $(42,018,169) | 10,223 |
| Balance, December 31, 2023 | 825,459 | $8 | $43,553,524 | $(44,281,526) | $(727,995) |
| Share-based compensation | – | – | 85,827 | – | 85,827 |
| Issuance of common shares related to restricted stock units | 4,261 | – | – | – | – |
| Issuance of common shares - equity line of credit | 452,343 | 5 | 1,449,527 | – | 1,449,532 |
| Issuance of commitment shares - note financing | 9,312 | – | 33,297 | – | 33,297 |
| Cashless exercise of pre-funded warrants | 2,915 | – | – | – | – |
| Issuance of common stock and warrants related to public offering, net issuance costs | 5,175,000 | 52 | 2,691,339 | – | 2,691,391 |
| Public offering and line of credit issuance costs | – | – | (399,106) | – | (399,106) |
| Issuance of common shares - debt for equity exchange | 644,142 | 6 | 1,771,600 | – | 1,771,606 |
| Round up conversion related to reverse stock split | 40,068 | – | – | – | – |
| Net income (loss) | – | – | – | (2,399,102) | (2,399,102) |
| Balance, March 31, 2024 | 7,153,500 | $72 | $49,186,006 | $(46,680,628) | 2,505,449 |
| Share-based compensation | – | – | 70,305 | – | 70,305 |
| Issuance of common shares related to restricted stock units | 7,171 | – | – | – | – |
| Issuance of common shares - equity line of credit | 1,050,000 | 10 | 304,490 | – | 304,500 |
| Net income (loss) | – | – | – | (1,238,077) | (1,238,077) |
| Balance, June 30, 2024 | 8,210,671 | $82 | $49,560,800 | $(47,918,705) | 1,642,177 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.